Currently, dual anti-HER2 therapy can further improve the outcomes in HER2-positive breast cancer patients with acceptable tolerance; therefore, dual anti-HER2 therapy is currently recommended as a first-line treatment globally and in China (Swain et al., 2020; Giordano et al., 2022; Li and Jiang, 2022). This evidence concerns the gene ERBB2 and breast carcinoma.